Nycomed Faces IP Suit Over Solaraze Gel

Law360, New York (March 18, 2011, 4:17 PM EDT) -- Pharmaceutical research company GlycoBioSciences Inc. filed suit in New York on Thursday against Nycomed US Inc., claiming that its Solaraze Gel skin condition treatment infringes two patents. 

Ontario, Canada-based GlycoBioSciences lodged its suit in the U.S. District Court for the Eastern District of New York, targeting Nycomed, Nycomed subsidiary Pharmaderm and Jagotec AG. 

The defendants make and sell Solaraze, a treatment for the chronic skin condition actinic keratosis, the complaint states. 

Melville, N.Y.-based Nycomed holds the new drug application for Solaraze, and exclusively licenses six Solaraze...
To view the full article, register now.

UK Financial Services

UK Financial Services

Read Our Latest UK Financial Services Coverage

Financial Services Law360 UK provides breaking news and analysis on the financial sector. Coverage includes UK and European Union policy, enforcement, and litigation involving banks, asset management firms, and other financial services organizations.